In the latest market close, Exact Sciences (EXAS) reached $63.24, with a -0.46% movement compared to the previous day. This change lagged the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.11%, and the technology-dominated Nasdaq saw an increase of 0.1%.Shares of the molecular diagnostics company witnessed a loss of 2.62% over the previous month, beating the performance of the Medical sector with its loss of 4.52% and the S&P 500's loss of 3.01%.Analysts and investors alike will b ...

Core Viewpoint - Exact Sciences (EXAS) is expected to report its first-quarter 2024 results on May 8, with a consensus estimate of a loss per share of 50 cents and revenues of $624.9 million [1][2]. Earnings Surprise History - Exact Sciences has consistently beaten earnings estimates in the last four quarters, achieving an average earnings surprise of 51.48% [2]. Previous Quarter Performance - In Q4 2023, Exact Sciences reported a net loss of 27 cents per share, an improvement from a loss of 72 cents in the previous year and better than the consensus estimate of a loss of 53 cents. This improvement was attributed to growth in the Screening and Precision Oncology segments, alongside strong adoption of Cologuard [3]. Revenue Segments - Exact Sciences reports revenues under three segments: Precision Oncology, Screening, and COVID-19 testing [4]. - The Precision Oncology segment is expected to see revenue growth driven by laboratory service revenues from Oncotype DX and therapy selection tests, with a consensus estimate of $159.3 million for Q1 2024 [4][5]. - The Screening segment is anticipated to generate revenues of $464.5 million in Q1 2024, supported by increased laboratory service revenues from Cologuard and Prevention Genetics tests [7]. Cologuard Adoption - Cologuard adoption has reached an all-time high, with 172,000 healthcare providers ordering the test, contributing positively to revenues [6]. Seasonal Trends - Management anticipates a sequential decline in screening revenues due to typical seasonal trends, as primary care utilization is lower during the holiday season, impacting the timing of Cologuard orders and completed tests [7]. COVID-19 Testing Segment - Exact Sciences has not recorded any revenues from the COVID-19 testing segment in the previous quarter, a trend expected to continue in Q1 2024 [8]. Earnings Prediction Model - The current model indicates a negative Earnings ESP of -27.27% for Exact Sciences, suggesting that an earnings beat is unlikely this quarter [9].

Market Performance - Exact Sciences (EXAS) closed at $63 22, with a -1% movement compared to the previous day, lagging behind the S&P 500's daily loss of 0 58% [1] - Over the past month, shares of Exact Sciences gained 3 17%, outperforming the Medical sector's loss of 6 07% and the S&P 500's loss of 1 09% [1] Earnings and Revenue Expectations - Exact Sciences is expected to post earnings of -$0 50 per share in its upcoming earnings report on May 8, 2024, marking a year-over-year decline of 19 05% [1] - The Zacks Consensus Estimate for revenue projects net sales of $624 95 million, up 3 73% from the year-ago period [1] - For the entire year, the Zacks Consensus Estimates forecast earnings of -$0 86 per share and revenue of $2 83 billion, indicating changes of +23 89% and +13 32%, respectively, compared to the previous year [2] Analyst Estimates and Revisions - Recent changes to analyst estimates for Exact Sciences should be noted, as positive alterations signify analyst optimism regarding the company's business and profitability [2] - The Zacks Consensus EPS estimate has remained unchanged over the last 30 days [3] Industry and Zacks Rank - Exact Sciences presently features a Zacks Rank of 2 (Buy) [3] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 82, placing it in the top 33% of all 250+ industries [3] - The Zacks Industry Rank shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [3]

Full disclosure, I’m not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks. For example, what many would consider the best Cathie Wood stocks to buy in April, and her two largest holdings were Coinbase (NASDAQ:COIN) and Tesla (NASDAQ:TSLA). Both companies’ valuations are in the stratosphere. And Coinbase is facing tremendous competition from Bitcoin (BTC-USD) ETFs, along with a potentially ruinous lawsuit by the SEC. Meanwhile Tesla is struggling amid a huge amount of competi ...

This company is innovating where it matters most, which could prove highly lucrative down the road.Cancer diagnostic specialist Exact Sciences (EXAS -0.04%) has lagged the market over the past three years. The pandemic and the economic troubles that followed disrupted the company's operations, and the healthcare leader remains unprofitable. However, one famous name on Wall Street continues to have faith in Exact Sciences.That person is Cathie Wood, CEO of Ark Invest, an investment management firm that still ...

Exact Sciences Corporation (EXAS) recently reported a promising outcome for the non-endoscopic Oncoguard Esophagus test, developed in collaboration with the Mayo Clinic Comprehensive Cancer Center. The test, currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE), has demonstrated high sensitivity and specificity.The findings from the test’s algorithm training and testing were recently published in the Clinical Gastroenterology and ...

Core Viewpoint - Exact Sciences has shown improvement in its financial performance, with a narrowed net loss and increased revenues, indicating potential for continued positive trends leading up to its next earnings release [2][3][4]. Financial Performance - The company reported a net loss of $0.27 per share for Q4 2023, an improvement from a loss of $0.72 per share in the same quarter last year [2]. - Full-year net loss was $1.13 per share, better than the Zacks Consensus Estimate of a loss of $1.39, and improved from a loss of $3.54 per share in 2022 [2]. - Q4 consolidated revenues reached $646.9 million, a 17% increase year-over-year, exceeding the Zacks Consensus Estimate by 2.4% [3]. - Total revenues for 2023 were $2.49 billion, beating the Zacks Consensus Estimate by 0.8% and increasing 19.9% from 2022 [3]. Revenue Segments - Screening revenues, including laboratory services from Cologuard, totaled $486.7 million, up 21% year-over-year, driven by increased adoption by healthcare providers [4]. - Precision Oncology revenues were $160.2 million, a 12% increase year-over-year, with international growth in Oncotype DX expanding by 48% [4]. - No revenues were recognized from COVID-19 testing in Q4, compared to $6.04 million in the previous year [4]. Margins and Expenses - Gross profit for the quarter rose 17% to $475 million, with a gross margin of 73.4%, an increase of 4 basis points [5]. - Research and development expenses increased by 21.9% to $114.9 million, while sales and marketing expenses decreased by 9.4% to $190.5 million [5]. - Adjusted operating loss was $50.9 million, an improvement from a loss of $92.5 million in the previous year [5]. Financial Position - At the end of Q4 2023, the company had cash and cash equivalents of $777.6 million, up from $632.1 million at the end of 2022, with no long-term debt [6]. 2024 Guidance - Exact Sciences expects total revenues for 2024 to be between $2.81 billion and $2.85 billion, with Screening revenues projected at $2.155 billion to $2.175 billion and Precision Oncology revenues at $655 million to $675 million [7]. Market Sentiment - There has been a downward trend in estimates revisions, with the consensus estimate shifting down by 21.32% recently [7]. - The company holds a Zacks Rank 2 (Buy), indicating expectations for above-average returns in the coming months [9]. Industry Comparison - Exact Sciences operates within the Zacks Medical - Biomedical and Genetics industry, where competitor Illumina reported revenues of $1.12 billion, reflecting a year-over-year increase of 3.6% [10].

Exact Sciences Corporation (EXAS) recently announced the online publication of the BLUE-C study results in The New England Journal of Medicine (NEJM). The 20,000-participant, multi-center and prospective study was designed to determine the performance characteristics of the company’s next-generation Cologuard Plus multitarget stool DNA test.The publication of the "Next-Generation Multitarget Stool DNA Test for Colorectal Cancer (CRC) Screening" peer-reviewed study in NEJM reflects a decade of Exact Sciences ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, " Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening", will also appear in the journal's March 14, 2024 print issue. The 20,000-participant BLUE-C study was designed to determine the performance characteristics of Exact Sciences’ ...

Exact Sciences (EXAS) closed the last trading session at $61.46, gaining 0.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $95.53 indicates a 55.4% upside potential.The mean estimate comprises 17 short-term price targets with a standard deviation of $15.39. While the lowest estimate of $73 indicates an 18.8% increase from the current price level, the most optimistic analyst expe ...